Thus, NFIX may directly regulate the activity of the CRABP2 promoter and NFIX mutations may alter CRABP2 expression in MSS patients, and NFIX may indirectly affect VCAM1 expression via the RA signaling pathway (Figure 5). Here, CRABP2 is linked to Marinesco-Sjogren syndrome.